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Cellular and animal models of skin 
alterations in the autism-related 
ADNP syndrome
Pilar Mollinedo1,5, Oxana Kapitansky2, Domingo Gonzalez-Lamuño3,5, Adi Zaslavsky2, 
Pedro Real  4, Illana Gozes2, Alberto Gandarillas5 & Jose L. Fernandez-Luna1,5
Mutations in ADNP have been recently associated with intellectual disability and autism spectrum 
disorder. However, the clinical features of patients with this syndrome are not fully identified, and 
no treatment currently exists for these patients. Here, we extended the ADNP syndrome phenotype 
describing skin abnormalities in both a patient with ADNP syndrome and an Adnp haploinsufficient 
mice. The patient displayed thin dermis, hyperkeratotic lesions in periarticular areas and delayed wound 
healing. Patient-derived skin keratinocytes showed reduced proliferation and increased differentiation. 
Additionally, detection of cell cycle markers indicated that mutant cells exhibited impaired cell 
cycle progression. Treatment of ADNP-deficient keratinocytes with the ADNP-derived NAP peptide 
significantly reduced the expression of differentiation markers. Sonography and immunofluorescence 
staining of epidermal layers revealed that the dermis was thinner in the patient than in a healthy 
control. Adnp haploinsufficient mice (Adnp+/−) mimicked the human condition showing reduced dermal 
thickness. Intranasal administration of NAP significantly increased dermal thickness and normalized 
the levels of cell cycle and differentiation markers. Our observations provide a novel activity of the 
autism-linked ADNP in the skin that may serve to define the clinical phenotype of patients with ADNP 
syndrome and provide an attractive therapeutic option for skin alterations in these patients.
Autism spectrum disorders (ASD) vary in presentation and severity and a number of ASD genes have been 
identified with the introduction of exome sequencing1,2. Analysis of patients with intellectual disability and their 
parents, can diagnose at least 16% of cases, mostly involving de novo mutations3. Recently, a number of patients 
with ASD, intellectual disability and various shared clinical features caused by mutations in Activity-Dependent 
Neuroprotective Protein (ADNP) have been reported4–6. All mutations were heterozygous frameshift or non-
sense changes located at the last exon of the gene and gave rise to premature stop codons. ADNP may par-
ticipate in chromatin remodeling, transcription and microtubule/autophagy regulation7,8. According to the 
Genotype-Tissue Expression (GTEx) database, ADNP gene is expressed in a wide variety of tissues and cell types 
including transformed lymphocytes and fibroblasts, primary and secondary sex organs, central and peripheral 
nervous systems and thyroid among others.
In mice, Adnp is essential for brain formation and Adnp haploinsuficiency is associated with cognitive and 
social deficits as well as tauopathy9. Interestingly, administration of NAP, an 8-aminoacid neuroprotective peptide 
derived from ADNP protein, ameliorated the short-term memory deficits in ApoE knockout mice, a model for 
Alzheimer disease10,11, and in Adnp+/− mice12. Although classified as a neurodevelopmental disorder, the ADNP 
syndrome, also called Helsmoortel-Van der Aa syndrome (MIM: 615873) presents with a plethora of clinical 
symptoms, including hypotonia, growth retardation, recurrent infections and hyperlaxity4 which reveals the mul-
tisystem character of this disorder. Studies on rare diseases are usually hampered by a lack of cellular models to 
analyze the response to potential treatments or decipher the molecular mechanisms underlying these conditions. 
Primary cell models are typically limited to renewable and easily accessible cell types, such as immortalized lym-
phocytes, fibroblasts or keratinocytes. As an example, primary fibroblasts from skin biopsy have been used to 
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establish cellular models of neurodegenerative diseases, such as Friedrich ataxia13 and Parkinson disease14. We 
now present novel data on the alterations of ADNP-deficient skin cells from a patient with ADNP syndrome, and 
reproduced the skin phenotypic changes in an Adnp+/− mouse model. Moreover, treatment of mice with NAP 
reverted the altered phenotype of the skin.
Materials and Methods
Phenotype of the patient. Our patient is an 11 year-old girl that was born at term after a normal gesta-
tion and delivery, to non-consanguineous healthy parents. At the neonatal period the patient presented marked 
irritability and at very early stages, she exhibited autistic-like behavior, marked gastrointestinal problems, psych-
omotor retardation, sleep disturbances, teeth grinding, delayed growth and cognitive disabilities. Mild dysmor-
phic features characteristic of the ADNP syndrome4, including prominent forehead, high hairline, notch of the 
eyelid, broad nasal bridge and thin upper lip, were also present. During early infancy gastrointestinal problems 
were mostly associated with recurrent intestinal parasitosis (Giardia Lamblia) and candidiasis. No infections 
in other systems were ever detected. The patient was treated with steroids and antibiotics with apparently good 
Figure 1. Skin alterations in a patient carrying a mutant ADNP. (a) Exome sequencing identified a p.Tyr719* 
mutation in the last exon of ADNP gene. (b) Skin thickening (arrowheads) of patient and control was assessed by 
sonography. Thickness of the epidermal layers (c) and the stratum corneum (d) was assessed by tissue staining with 
anti-KRT10 antibodies. Plots show the mean ± SD of independent stainings of five different skin sections (at least 
three quantifications per section). (e) Immunofluorescence images showing the thickness of the stratum corneum 
(white arrowheads) and the epidermal layers (red arrowheads) as determined by staining with hematoxylin-eosin 
and anti-KRT10 antibodies. Scale bar: 500 μm. (f) Hyperkeratotic skin in the knee of the patient.
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outcome. Different transient endocrine disorders such as hypothyroidism with high TSH, hypocortisolemia and 
hypoglycemia were also identified when gastrointestinal disorders were present. She was firstly diagnosed with 
non-progressive neurodevelopmental disorder that resembled a mild form of Rett-like syndrome with mental 
retardation, learning disabilities and autism.
Sonography. Thickness of the dermis at the volar forearm was determined by high resolution ultrasound 
visualization with high frequency probes (18–22 MHz). A standard echographic gel was used as the coupling 
medium between the transducer and the patient’s skin. Minimal pressure was applied to preserve the thickness 
and echogenicity of the dermis.
Primary cell cultures. Primary skin cells were isolated from forearm-skin biopsy. This study was approved 
by the ethics committee of Valdecilla University Hospital (Santander, Spain) and an informed written consent 
from the parents of the child was obtained. All research was performed in accordance with relevant guidelines 
and regulations. Keratinocytes were cultured in the presence of a feeder layer of mitomycin C-inactivated J2–3T3 
fibroblasts in Ham’s 12 medium/Dulbecco’s modified Eagle medium (DMEM) (Invitrogen, Carlsbad, CA), sup-
plemented with 10% fetal bovine serum, 1.8 × 10−4 M adenine, 0.5 µg/ml hydrocortisone, 5 µg/ml insulin, 10−10 M 
cholera enterotoxin and 10 ng/ml epidermal growth factor. Primary fibroblasts were cultured in DMEM supple-
mented with 10% fetal bovine serum and 0.5% L-glutamine.
Primary keratinocytes and fibroblasts were treated with 100 nM or 600 nM NAP peptide (amino acid 
sequence, NAPVSIPQ) (GenScript, Piscataway, NJ) for different times as indicated. Cells at low passages (between 
1 and 5) were used for all experiments.
For the wound-healing assay, fibroblasts were grown to confluency in 24-well plates and the monolayer of cells 
was scratched with a needle. The percentage of scratch closure was determined following 24 h of culture.
Clonogenicity assays. For clonogenicity assays, 2500 keratinocytes per well were plated in 6-well plates. 
About 10 days later, cell cultures were fixed with 3,8% formaldehyde in PBS for 10 minutes and stained with 
rhodanile blue as described previously15. Cell density was quantitated by measuring absorbance at 400–700 nm 
Figure 2. Proliferation of mutant skin cells. (a) Keratinocytes, K, and fibroblasts, F, from the patient carry 
the mutant ADNP allele as assessed by allele-specific PCR. Mutant keratinocytes and fibroblasts showed 
reduced proliferative activity as determined by Neubauer chamber cell counting (b) and a label-free method 
(xCELLigence) (c). Plots show the mean ± SD of at least three independent experiments.
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with a transmission optical microscopy (Nikon, Tokyo, Japan) connected to a spectrograph (Andor, Belfast, UK). 
Data were obtained from three independent assays.
Proliferation assays. Keratinocytes (70000 cells/well) were plated in 6-well plates and cultured in 
the medium described above and proliferation was quantitated at different time points by cell counting with 
Neubauer chamber. To assess fibroblasts proliferation, 2500 cells per well were seeded on conductive microtiter 
plates (E-plate 16) and monitored during 120 hours using an xCELLigence DP instrument (ACEA Bioscence, San 
Diego, CA).
Immunofluorescence. Keratinocytes were grown on glass coverslips, fixed with 3,8% formaldehyde in PBS 
for 10 minutes and permeabilized with cold methanol for 5 minutes or fixed with cold methanol for 10 min-
utes. Paraffin-embedded skin sections were prepared following convential procedures. Samples were incu-
bated for 1 hour (cells) or overnight (sections) in a wet chamber with antibodies against keratin 10 (sc-23877), 
phospho-histone H3 (sc-8656-R), cyclin A (sc-56299), cyclin E (sc-198), αTubulin (SC-23948) (all from Santa 
Cruz, CA, USA), involucrin (I-9018, Sigma-Aldrich, Inc), keratin 1 (PRB-149P, Covance, Vienna, VA, USA) or 
Ki67 (ab16667, Abcam, Cambridge, UK). Then, primary antibodies were revealed with Alexa Fluor-conjugated 
goat anti rabbit or anti mouse antibodies (Jackson ImmunoResearch, PA, USA). Samples were then incubated 
with 0.2 µg/ml DAPI (Vector Lab, Burlingame, CA). Coverslips were mounted with Prolong Gold Antifade 
Reagent (ThermoFisher Scientific, Waltham, MA) and cells were visualized and photographed with a Zeiss fluo-
rescent microscopy. Immunofluorescence staining was scored by counting 400 cells.
Flow cytometry. Keratinocytes were harvested, fixed with 3,7% paraformaldehyde or with cold 70% ethanol, 
and stained for involucrin or keratin 1. Isotype IgG was used as negative control. Alexa Fluor-labeled second-
ary antibodies were then used and labelled cells were analysed by flow cytometry (FACSCanto, BD Biosciences, 
Franklin Lakes, NJ) using the FACSDIVA software (BD Biosciences).
Whole exome sequencing. Whole blood was obtained from the patient and her parents and genomic 
DNA was extracted from mononuclear cells using the QIAamp DNA blood kit (Qiagen, Hamburg, Germany). 
Whole exomes were sequenced by using a HiSeq. 2000 sequencer (Illumina, CA, USA). Sequencing reads were 
aligned against the human reference genome (hg19) using BWA with the default parameters. Several tools (SAM, 
Figure 3. Morphology and differentiation status of mutant cells. (a) Morphological features of keratinocytes 
and fibroblasts were assessed by phase contrast microscopy, Scale bar: 50 μm. (b,c) The clonogenic capacity 
of mutant and wild type keratinocytes was determined by measuring absorbance at 400–700 nm of rhodanile 
blue-stained cells. (d,e) Terminal differentiation markers of keratinocytes KRT1 and IVL were analyzed in both 
wild type and mutant cells by flow cytometry. Histograms show the mean ± SD of at least three independent 
experiments.
www.nature.com/scientificreports/
5Scientific RePoRts |           (2019) 9:736  | DOI:10.1038/s41598-018-36859-2
GATK, Picard) for manipulating alignments including sorting, merging and indexing the BAM files were used. 
Single nucleotide variant and indel calling was performed using GATK Unified Genotyper. Variants were anno-
tated using snpEff and association studies were performed using Plink software. To confirm the mutation in 
cellular models, we used an allele-specific PCR from genomic DNA with two allele-discriminating forward prim-
ers 5′CACCTGTGAAGCGCACTTAC 3′ (for wild type allele) and 5′CACCTGTGAAGCGCACTTAA3′ (for mutant 
allele) and a common reverse primer 5′GGGATAGGGCTGTTTGTTGAA3′. Fragments (206 bp) were resolved by 
agarose gel electrophoresis.
Mouse model. All procedures involving animals have been approved by the Animal Care and Use Committee 
of Tel Aviv University and the Israeli Ministry of Health. All experiments were performed in accordance with rele-
vant guidelines and regulations. Two-month old Adnp heterozygous and littermates control mice12, outbred with 
ICR16 were housed in a 12-h light/12-h dark cycle facility, and free access to rodent chow and water was available. 
For intranasal administration, NAP peptide was dissolved in a vehicle solution and administered as described12,17. 
Nasal NAP application (0.5 μg NAP in 5 μl vehicle solution) was performed daily, once a day, for 6 weeks (5 days 
a week). Vehicle-treated mice were maintained until the age of 4.5 months.
Primary fibroblasts were prepared from tail tips of 4.5-month-old Adnp+/− (n = 3) and Adnp+/+ (n = 3) 
female mice. Tail tips were incubated in a solution containing 0.1% collagenase at 37 °C for 2 h following standard 
procedures18. Isolated fibroblasts were plated at 5000 cells/well on 96-well plates in triplicate. When indicated, 
180 nM NAP was added to fibroblast cultures. For tissue analyses, skins were frozen and embedded in optimal 
cutting temperature compound as described19.
Figure 4. Morphological features of patient’s skin. (a) Skin sections from the patient (carrying an ADNP 
mutant allele) and an age-matched healthy control (ADNP wt) were labelled with antibodies against CCNA and 
KRT10 markers to assess their expression and distribution along epidermal layers. Nuclei were counterstained 
with DAPI. (b) More than 100 cells for both patient and control samples were counted using ImageJ software 
and the percentage of cells expressing CCNA was determined. (c) Nuclear distribution of phospho-histone H3 
that marks chromatin condensation changes during the cell cycle. (d) The punctate staining of phospho-histone 
H3 associated with chromatin condensation (CCpH3 + cells) was determined in at least 100 cells of both 
wild type and mutant genotypes. Scale bar in all immunofluorescence images: 500 μm. Histogram shows the 
mean ± SD of at least three independent experiments.
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Statistical analysis. All statistics were calculated with the SPSS statistical package (version 13.0) or Sigma 
Plot (version 11.0, Chicago, IL). The Student t test was used to compare continuous variables, summarized as 
means ± SD or means ± SEM, between two groups. Multiple comparisons utilized two-way ANOVA analysis of 
variance followed by Fisher’s Least Significant Difference.
Results
Characterization of skin cells from a patient with ADNP syndrome. The clinical phenotype of the 
ADNP syndrome is not fully characterized. This syndrome is a neurodevelopmental disorder and it has also 
been shown that children with ADNP syndrome exhibited early primary tooth eruption5. The nervous system 
and tooth enamel along with the epidermis have a common embryonic origin, the ectoderm. Thus, we aimed to 
study the skin of a patient diagnosed with ADNP syndrome in our hospital. This tissue has the advantage that 
a biopsy can be easily performed and skin cells can be obtained and cultured to generate a cellular model of the 
disease. The patient carried an ADNP p.Tyr719* causal heterozygous truncating mutation (Fig. 1a), identified in 
other 23 children with ADNP syndrome from more than 100 cases diagnosed worldwide6,20. ADNP protein is 
mainly localized in the nucleus by means of its nuclear localization signal. However, the truncated protein shows 
a cytoplasmic distribution likely due to a partially deleted nuclear localization signal21. Thus, p.Tyr719* variant 
lacks the nuclear activities of ADNP. A sonographic study revealed that the dermis of the patient was thinner 
compared with healthy controls (Fig. 1b). Dermis is the major contributor to the variation in skin thickness and is 
Figure 5. In vitro response of skin cells to neuroprotectant peptide NAP. (a) Proliferation of wild type and 
mutant keratinocytes exposed to NAP at different time intervals. The effect of NAP on the differentiation of 
keratinocytes was assessed by counting the number of cells expressing the differentiation markers KRT10 (b) 
KRT1 (c) and IVL (d). (e) Proliferative response of fibroblasts during the first 100 h following exposure to NAP 
(a.u., arbitrary units). (f,g) Detachment from the substrate, a required step for differentiating keratinocytes 
to migrate, was evaluated after 2 and 5 days of culture in the presence of NAP. (h) Quantification of fibroblast 
migration was determined as the percentage of scratch closure. Histograms show the mean ± SD of at least three 
independent experiments.
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mainly determined by its collagen content22. Dermal thickness in the ventral forearm of the patient was 0.9 mm, 
whereas the skin of 8 controls of the same sex, weight and age had a thickness of 1.2 ± 0.1 mm, which is in the 
range of normal values as previously described23. Additionally, the epidermal layers beneath the stratum corneum 
were thinner in our patient than in a normal control. However, the fully differentiated stratum corneum of the 
epidermis, was about 2-fold thicker in the patient than in the control (Fig. 1c–e) as determined by tissue staining 
with hematoxylin and eosin and immunolabeling of KRT10 that is expressed in all suprabasal cell layers. This 
result is consistent with the hyperkeratotic lesions observed in the skin of periarticular areas (Fig. 1f). Although 
all sections from the skin’s patient were processed in parallel with controls, we can not rule out an expansion of 
the stratum corneum thickness due to non-intrinsic factors. During the course of this study, we obtained ultra-
sound data of the skin of another patient, a six-year-old boy carrying a novel truncating mutation (c.138_139del, 
pPhe46Leufs*52). Sonography revealed that dermal thickness was 0.73 mm, confirming the previous result and 
extending this skin alteration to other mutations in the ADNP gene. This second mutation generates a short 
fragment at the N-terminal end of the protein that according to recently published data, should not be expressed 
because fragments up to residue 447 show little or no expression due to degradation by the proteasome21. A 
survey among 23 ADNP families was conducted through the ADNP parent support group on Facebook5. Nine 
children presented the pTyr719* mutation and in seven of these cases parents referred skin alterations including 
delicate skin, low wound healing compared with their other healthy child, eczema and rashes. Assessment of 
whether the skin phenotype reported here is specific for particular mutations will require clinical and echo-
graphic evaluation of the skin in more patients and in vitro skin studies whenever possible.
Both keratinocytes and fibroblasts were obtained from a forearm skin biopsy of the patient and a healthy 
control of the same age and maintained in culture for a limited number of passes (usually less than 5). These skin 
cells, carrying the ADNP mutation (Figs 2a and S6), displayed reduced proliferation compared to wild type cells 
(Fig. 2b,c). Mutant keratinocytes represented a high-scatter population of larger (forward scatter) and more com-
plex (side scatter) cells as determined by flow cytometry analysis (Supplementary Fig. S1a,b) and contained larger 
nuclei (Supplementary Fig. S1c). These features are consistent with terminal differentiation of keratinocytes24. 
Mutant keratinocyte colonies contained round-up cells with larger intercellular spaces, suggesting reduced cell 
Figure 6. Skin features in an Adnp haploinsufficient mouse model. (a) Fibroblasts from Adnp+/− and Adnp+/+ 
mice were cultured with and without NAP and their proliferative response was assessed at multiple time points. 
Error bars represent means ± SEM of 4 images per well in triplicate. (b) Differences in dermal thickness between 
Adnp+/− and Adnp+/+ mice and the effect of the administration of NAP on skin thickening. (c) Expression and 
localization of cyclin A1 (Ccna1) in skin sections of Adnp+/+ and Adnp+/− mice after intranasal administration of 
the neuroprotective peptide NAP. Tissue images were examined by slide scanner at 40x magnification. (d) Intensity 
of Ccna1 signals were determined by Image J software in the ear skin. Histograms show the means ± SEM of at 
least three independent experiments. Nuclei were stained with DAPI. Scale bar: 15 μm.
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adhesion (Fig. 3a). Mutant fibroblasts were less fusiform and displayed shorter and disordered filopodia than the 
control counterpart (Fig. 3a). Clonogenic assays further confirmed that cell proliferation was notably impaired 
in keratinocytes carrying mutant ADNP (Fig. 3b,c). Reduced proliferation was accompanied by increased dif-
ferentiation as assessed by quantitating the proportion of keratinocytes that expressed Keratin 1 (KRT1) and 
Involucrin (IVL) epidermal differentiation markers (Fig. 3d,e). To further analyze the effect of mutant ADNP on 
proliferation, we studied the expression of cell cycle regulatory proteins in the patient’s epidermal tissue. Cyclin A 
(CCNA), which peaks at G2 phase and is abruptly destroyed at the beginning of mitosis, accumulates following 
G2 arrest. Interestingly, Cyclin A accumulated in the peribasal epidermal layer of the patient, lining the supra-
basal compartment containing Keratin 10-positive differentiated cells (Fig. 4a,b). In addition, phospho-histone 
H3 marks highly condensed chromatin, corresponding to metaphase chromosomes, in control’s skin basal cells, 
whereas it associated with open chromatin (interphase chromosomes) in the patient (Fig. 4c,d). On the contrary, 
cyclin E (CCNE), needed for suprabasal keratinocyte growth25, was barely detected in the patient’s suprabasal epi-
dermis (Supplementary Fig. S2a). Cycling cells in the epidermal basal layer, frequent in normal controls, were also 
drastically reduced in the patient as determined by labeling with the proliferation marker Ki67 (Supplementary 
Fig. S2b). These data are consistent with a growth alteration due to G2 or mitosis defects.
In vitro response of skin cells to neuroprotectant peptide NAP. NAP (NAPVSIPQ), the shortest 
active peptide of ADNP, has been shown to increase ADNP activity26. Treatment of keratinocytes with 600 nM 
NAP showed a reproducible trend to increase the proliferation of mutant cells but it did not reach statistical 
significance (Fig. 5a). However, NAP treatment reduced the number of mutant and also wild-type cells express-
ing differentiation markers KRT10, KRT1 and IVL as assessed by flow cytometry (Fig. 5b–d) and immunoflu-
orescence staining (Supplementary Fig. S3). Similar data were obtained when mutant fibroblasts were exposed 
to NAP, showing a small but significant (p = 0.005) increase in cell proliferation in a time-dependent manner, 
whereas wild type cells did not show any response to the peptide (Fig. 5e). NAP peptide specifically binds tubulin 
and stimulates microtubule assembly27. This interaction might affect processes where tubulins play key roles 
including proliferation and differentiation. We immunostained both wild type and mutant keratinocytes with 
antibodies against αTubulin and consistently observed a decrease in αTubulin protein levels in mutant cells that 
were recovered at least in part by adding NAP (Supplementary Fig. S4), suggesting that NAP might have a tubulin 
stabilization role. Migration is a required step for differentiating keratinocytes to reach the upper layers of the 
skin and it needs that both cell-cell and cell-substrate contacts are remodeled to allow cell detachment from the 
basement membrane. Mutant keratinocytes showed a higher capacity to detach from the substrate after 2 days of 
culture compared with wild type cells (p < 0.001). However, exposure to NAP drastically reduced the number of 
detached mutant cells to levels similar to those of wild type keratinocytes (Fig. 5f,g). Keratinocytes depend on cell 
adhesion to maintain their proliferation15. Thus, our data suggest a cell adhesion defect caused by a deficiency of 
ADNP. In order to analyze the reduced healing capacity of ADNP mutant carriers and the effect of NAP, we per-
formed a wound healing assay, widely used to mimic cell migration during wound healing in vivo28. We showed 
a reduced migration of mutant fibroblasts compared with wild type cells (Fig. 5h). Moreover, exposure of both 
mutant and wild type cells to NAP significantly increased the repopulation of the scratch area.
Effects of NAP on the skin of an Adnp-deficient mouse model. Dermal skin fibroblasts were isolated 
from transgenic mice carrying only one functional copy of the Adnp gene (Adnp+/−)12. Adnp+/− cells exhibited 
a significant decreased proliferative activity compared with wild type (Adnp+/+) fibroblasts (Fig. 6a). Although 
there was a tendency toward increased proliferation of Adnp+/− cells following exposure to NAP, it did not reach 
the threshold for statistical significance. The effect of NAP on the skin of transgenic mice was also studied fol-
lowing intranasal administration of the peptide. Epidermis was thinner in Adnp+/− mice compared with Adnp+/+ 
control, and treatment with NAP significantly increased dermal thickness (Fig. 6b). Immunostaining of skin 
samples revealed that Ccna1 protein levels were significantly higher in Adnp+/− mice compared to controls and 
fully normalized after NAP administration (Fig. 6c,d). Similar to the pattern observed in the patient, Ccna1 
was expressed in the peribasal layer, lining the suprabasal area (Fig. 6c). Also consistent with patient’s skin data, 
Keratin 10, localized in the suprabasal compartment, showed increased levels in Adnp+/− mice, that were normal-
ized following treatment with NAP (Supplementary Fig. S5a,b).
Discussion
We have described the biological alterations of skin cells in a patient with ADNP syndrome. On the basis of the 
current knowledge of this syndrome, epidermal defects have not been included within the symptoms caused by 
ADNP gene mutations. However, when parents were consulted by means of a survey of ADNP families through 
the ADNP parent support group on Facebook5, seven out of 9 children carrying the pTyr719* mutation pre-
sented, as referred by their parents, skin alterations, mainly delicate skin, low wound healing, eczema and rashes. 
The cellular alterations found are focused on keratinocytes, the most prevalent cell type in the epidermis, and 
fibroblasts, the predominant cell type in the dermis. It has been described that ADNP is essential for brain forma-
tion29 and mutations in ADNP, similar to the one described here, are associated with delayed brain development6. 
In line with this, ADNP mutations also resulted in thinner tooth enamel5. Interestingly, we have shown that a 
truncating mutation in ADNP resulted in thinner skin. It is noteworthy that brain, tooth enamel and epidermis 
have a commom embryonal origin as they all derive from the ectoderm. In vitro culture of mutant keratinocytes 
and fibroblasts revealed a reduced proliferative activity compared with cells from healthy donors. Fibroblast pro-
liferation and keratinocyte differentiation are among the key steps during wound healing30. Keratinocytes carry-
ing mutant ADNP have increased differentiation with higher levels of terminal differentiation markers. Epidermal 
keratinocytes evolve from undifferentiated basal cells to fully differentiated cornified cells that compose the stra-
tum corneum. Consistently, the reduced proliferative activity of skin cells may be the cause of a thinner skin 
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observed in the patient by ultrasound imaging and the increased differentiation potential of keratinocytes may 
explain the hyperkeratotic lesions in the skin of the patient as a result of a thicker stratum corneum. ADNP 
protein contains a neuroprotective peptide, NAP, that increases ADNP’s activity at the cellular level26 and reverts 
abnormal behavior in Adnp haploinsufficient mice12. In vitro treatment of keratinocytes or fibroblasts with NAP 
partially reverted their proliferation and differentiation deficiencies. Interestingly, while we did not observe a 
significant proliferative response to NAP in mouse fibroblasts (Adnp+/−), there was a small but significant effect 
on the patient’s fibroblasts, suggesting that the response may be mutation-specific. Alternatively, intrinsic bio-
logical differences between mouse and human fibroblasts may account for the differential response to NAP. In 
line with this, it has been described a different cellular response to genotoxic agents between mouse and human 
fibroblasts31. Cell attachment, which is associated with wound healing, was impaired in ADNP mutated keratino-
cytes and partially corrected by NAP treatment. Consistent with this result, NAP has been shown to antagonize 
ethanol inhibition of cell adhesion in different cell lines32. Previous data suggested that NAP was neuroprotective 
by controlling microtubule dynamics26, promoting neurite outgrowth33. It is likely that a similar mechanism could 
increase proliferation of skin cells as reorganization of the microtubule network for chromosomal segregation is 
required for cell division. Failure to separate the chromosomes can trigger a G2/M phase arrest, blocking entry 
into mitosis. In line with this, we have demonstrated that cyclin A, which is upregulated at G2 and destroyed 
before mitosis, accumulates in patient’s epidermis, whereas cyclin E that appears at G1 to regulate the G1/S phase 
transition is barely detected. These data suggest that a deficient microtubule reorganization in epithelial cells 
carrying mutant ADNP may promote blockade at G2/M phase of the cell cycle avoiding cells to progress through 
mitosis. Interestingly, a prolonged mitotic blockade triggers keratinocyte differentiation25, which might explain 
the increased differentiation of mutant keratinocytes. A mechanistic explanation to these NAP activities may 
reside in the interaction of NAP with microtubule-associated proteins. It has been described that SIP motif in the 
NAP peptide (NAPVSIPQ) interacts with microtubule end-binding proteins such as the EB1 protein family26. 
EB1 interacts with other microtubule-associated proteins to regulate Golgi dynamics and vesicle transport in 
different cell types including epithelial cells34, and it is also important for positioning the mitotic spindle35. Thus, 
NAP may have both nuclear and cytoplasmic activities through microtubule dynamics to facilitate cell division 
and cell migration in heterozygous carriers of a functionally defective ADNP variant. In line with this, we showed 
reduced protein levels of αTubulin in mutant cells that were partially recovered with NAP. A likely explanation 
is that part of the αTubulin proteins may remain as monomers in ADNP-deficient cells and are degraded by 
the proteasome. Degradation of monomeric tubulin has been previously described in different cell types due to 
misfolded proteins or destabilization of microtubules27,36. Consistently, NAP stimulates microtubule assembly 
in vitro37. Our in vitro data were reproduced in an Adnp heterozygous mouse model12. In Adnp+/− mice, dermal 
thickness increased following intranasal administration of NAP and this was accompanied by normalization 
of the levels of cell cycle and differentiation markers. Biological activity of NAP in this mouse model has been 
described and data showed that NAP treatment partially ameliorated cognitive deficits12. These in vivo results 
have fostered a number of clinical trials in tauopathies and schizophrenia9. Recently it has been described that 
premature primary tooth eruption in children with ADNP syndrome may help early and simple diagnosis5. Our 
data paves the way to consider skin alterations as another feature of the ADNP syndrome that can be easily iden-
tified by sonography and could be a potential simple surrogate marker for future clinical trials.
In summary, we have shown that skin cells with an ADNP mutation suffer reduced proliferation and increased 
terminal differentiation that may lead to thinner epidermis and a delay in wound healing and to a thickening of 
the cornified layer that may cause hyperkeratotic lesions.
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